Appointment of new CFO

August 1, 2026

The board of ChemoMetec has appointed Phillip Massie Price as the new Chief Financial Officer (CFO), effective 3 August 2026. Price previously served as Director of Corporate Finance at Unimed, a global healthcare group, and held the position of Interim Group CFO at LiqTech International, Inc., a Nasdaq-listed company where he led Group Finance.

Phillip Massie Price, 34, has a background in auditing and holds an MSc in Business Administration and Auditing from Copenhagen Business School. The board has reached an agreement with the current CFO, Kim Nicolajsen, to resign from his position concurrently with Price's appointment.

Following this transition, CEO Martin Helbo Behrens and CFO Phillip Massie Price will constitute the executive management team of ChemoMetec.

ChemoMetec develops, manufactures and markets instruments for cell counting and various other measurements, targeting the pharmaceutical, biotech and agricultural industries globally. Founded in 1997, ChemoMetec is listed on the Nasdaq Copenhagen stock exchange.

For further information, contact Chairman of the Board Niels Thestrup at (+45) 3370 2000 or CEO Martin Helbo Behrens at (+45) 8110 0680.

Disclaimer: This press release has been distributed on behalf of the issuing organization. PR Gun acts solely as a distribution platform and has not independently verified the accuracy, completeness, or validity of the statements contained herein.